CUMULATIVE
SUPPLEMENT 2
FEBRUARY 2001



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

Department of Health and Human Services
Public Health Service
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Information Technology
Division of Data Management and Services

2001

Prepared By
Division of Data Management and Services
Office of Information Technology
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

Cumulative Supplement 2

February 2001

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

CUMULATIVE SUPPLEMENT 2
FEBRUARY 2001

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 21st Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 21st Edition List will then be added to the "Discontinued Drug Product List" appearing in the 22nd Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated

Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
NOVOPHARM LTD (NOVOPHARM)	TEVA PHARMACEUTICALS USA (TEVA)
NOVOPHARM PHARMACEUTICAL CO (NOVOPHARM PHARM)	TEVA PHARMACEUTICALS USA (TEVA)
NOVOPHARM NC INC (NOVOPHARM NC)	TEVA PHARMACEUTICALS USA (TEVA)

1.3 AVAILABILITY OF THE EDITION

The 21st Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is $101.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at http://www.fda.gov/cder/orange/adp.htm.

The Internet version of the hard copy monthly supplement is at http://www.fda.gov/cder/orange/supplement/cspreface.htm. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 21st annual edition of the 2000 Orange Book Patent and Exclusivity List is at http://www.fda.gov/cder/orange/21bookpub.pdf.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at http://www.fda.gov/cder/orange/supplement/patents.pdf.

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at http://www.fda.gov/cder/orange/docket.pdf. It is updated monthly as soon as available and as otherwise needed.

The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:
http://www.fda.gov/cder/orange/patdecl.pdf
http://www.fda.gov/cder/orange/patdecl.html

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.4 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2000) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2000	MAR 2001	JUN 2001	SEP 2001
	10360			
DRUG PRODUCTS LISTED	2682 (25.9%)			
SINGLE SOURCE	7568 (73.1%)			
MULTISOURCE	7257 (70.0%)			
THERAPEUTICALLY EQUIVALENT				
NOT THERAPEUTICALLY EQUIVALENT	311 (3.0%)			
EXCEPTIONS[1]	110 (1.1%)			
NEW MOLECULAR ENTITIES APPROVED	2			
NUMBER OF APPLICANTS	594			

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

Please Note

1.5 CUMULATIVE SUPPLEMENT LEGEND

The 21st Edition Orange book (OB) Cumulative Supplement (CS) layout has changed. The new format follows the Annual Edition and previous CS format. The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form;Route and then by trade name. The manner of displaying the individual product information has changed.

The individual product record follows the previous format layout for Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. Two new columns have been added to provide more information. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form;route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product throuth the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
CTNA	Change. Trade Name.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

ACETAMINOPHEN; BUTALBITAL
CAPSULE; ORAL

>D>		TRIAPRIN					
>D>		DUNHALL	325MG;50MG	N89268 001	JUL 02, 1987	FEB	WDRP
>A>		@	325MG;50MG	N89268 001	JUL 02, 1987	FEB	WDRP

ACETAMINOPHEN; BUTALBITAL; CAFFEINE
CAPSULE; ORAL

>D>		ANOQUAN					
>D>	AB	ROBERTS AND HAUCK	325MG;50MG;40MG	N87628 001	OCT 01, 1986	FEB	WDRP
>A>		@	325MG;50MG;40MG	N87628 001	OCT 01, 1986	FEB	WDRP

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE
TABLET; ORAL
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

	+	MIKART	712.8MG;60MG;32MG	N40316 001	APR 28, 1999	JAN	CTNA

ACETAMINOPHEN; CODEINE PHOSPHATE
TABLET; ORAL

>D>		CAPITAL WITH CODEINE					
>D>	+	CARNRICK	325MG;30MG	N83643 001	MAY 31, 1974	FEB	WDRP
>A>		@	325MG;30MG	N83643 001	MAY 31, 1974	FEB	WDRP

ACETAMINOPHEN; HYDROCODONE BITARTRATE
TABLET; ORAL

		LORTAB					
AA	+	WATSON LABS	325MG;5MG	N40099 001	JUN 25, 1997	JAN	CAHN

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE
TABLET; ORAL
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

>A>	AB	MALLINCKRODT	650MG;100MG	N75738 001	FEB 02, 2001	FEB	NEWA
>A>	AB	VINTAGE PHARMS	325MG;50MG	N74843 002	FEB 15, 2001	FEB	NEWA

ALBUTEROL SULFATE
SOLUTION; INHALATION
ALBUTEROL SULFATE

>A>	AN	ROXANE	EQ 0.083% BASE	N75129 001	FEB 13, 2001	FEB	NEWA

AMIODARONE HYDROCHLORIDE
TABLET; ORAL
AMIODARONE HCL

	AB	BARR	200MG	N75389 001	JAN 25, 2001	JAN	NEWA

AMOXICILLIN
CAPSULE; ORAL
AMOXICILLIN

>D>	AB	LABS ATRAL	250MG	N62528 001	AUG 07, 1985	FEB	WDRP
>D>	AB		500MG	N62528 002	AUG 07, 1985	FEB	WDRP
>A>		@	250MG	N62528 001	AUG 07, 1985	FEB	WDRP
>A>		@	500MG	N62528 002	AUG 07, 1985	FEB	WDRP

AMPHOTERICIN B
INJECTABLE, LIPID COMPLEX; INJECTION
AMPHOTEC

>D>		+	ALZA	50MG/VIAL	N50729 001	NOV 22, 1996	FEB	CAHN
>D>		+		100MG/VIAL	N50729 002	NOV 22, 1996	FEB	CAHN
>A>		+	INTERMUNE PHARMS	50MG/VIAL	N50729 001	NOV 22, 1996	FEB	CAHN
>A>		+		100MG/VIAL	N50729 002	NOV 22, 1996	FEB	CAHN

AMPICILLIN/AMPICILLIN TRIHYDRATE
FOR SUSPENSION; ORAL
TOTACILLIN

>D>	AB		SMITHKLINE BEECHAM	EQ 125MG BASE/5ML	N60666 001	MAY 07, 1970	FEB	WDRP
>D>	AB			EQ 250MG BASE/5ML	N60666 002	MAY 07, 1970	FEB	WDRP
>A>		@		EQ 125MG BASE/5ML	N60666 001	MAY 07, 1970	FEB	WDRP
>A>		@		EQ 250MG BASE/5ML	N60666 002	MAY 07, 1970	FEB	WDRP

>A> ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K
>A> INJECTABLE; IV (INFUSION)
>A> INFUVITE PEDIATRIC

>A>		+	SABEX	80MG;0.02MG;400 IU;0.001MG; 5MG;0.14MG;17MG;1MG;1.4MG; 1.2MG;7 IU;2,300 IU;0.2MG (ALL POTENCIES PER VIAL)	N21265 001	FEB 21, 2001	FEB	NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
>A> FOR SOLUTION; IV (INFUSION)
>A> M.V.I. PEDIATRIC

>A>		+	ASTRAZENECA	80MG/VIAL;0.02MG/VIAL; 0.001MG/VIAL;5MG/VIAL;0.01MG/VIAL; 0.14MG/VIAL;17MG/VIAL; 0.2MG/VIAL;EQ 1MG BASE/VIAL; 1.4MG/VIAL;EQ1.2MG BASE/VIAL; 0.7MG/VIAL	N18920 001	SEP 21, 2000	FEB	NEWA

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE
TABLET; ORAL
INVAGESIC

	AB		GENEVA PHARMS TECH	385MG;30MG;25MG	N74817 001	NOV 27, 1996	JAN	CAHN

INVAGESIC FORTE

	AB		GENEVA PHARMS TECH	770MG;60MG;50MG	N74817 002	NOV 27, 1996	JAN	CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE
TABLET; ORAL
DIPHENOXYLATE HCL AND ATROPINE SULFATE

>D>	AA		INWOOD LABS	0.025MG;2.5MG	N85509 001	MAR 09, 1978	FEB	WDRP
>A>		@		0.025MG;2.5MG	N85509 001	MAR 09, 1978	FEB	WDRP

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

>D>		NEO-POLYCIN					
>D>		DOW PHARM	500 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N60647 001	APR 19, 1954	FEB	WDRP
>A>		@	500 UNITS/GM;EQ 3.5MG BASE/GM 10,000 UNITS/GM	N60647 001	APR 19, 1954	FEB	WDRP

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

AB	TEVA	2.5MG;6.25MG	N75686 001	JAN 19, 2001	JAN	NEWA
AB		5MG;6.25MG	N75686 002	JAN 19, 2001	JAN	NEWA
AB		10MG;6.25MG	N75686 003	JAN 19, 2001	JAN	NEWA

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

AB	GENEVA PHARMS TECH	12.5MG	N74481 001	FEB 13, 1996	JAN	CAHN
AB		25MG	N74481 002	FEB 13, 1996	JAN	CAHN
AB		50MG	N74481 003	FEB 13, 1996	JAN	CAHN
AB		100MG	N74481 004	FEB 13, 1996	JAN	CAHN

CARBACHOL

SOLUTION; INTRAOCULAR

CARBASTAT

>D> AT	CIBA	0.01%	N73677 001	APR 28, 1995	FEB	CAHN
>A> AT	NOVARTIS	0.01%	N73677 001	APR 28, 1995	FEB	CAHN

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

>D> AB	SCS	10MG;100MG	N74080 001	MAR 25, 1994	FEB	WDRP
>D> AB		25MG;100MG	N74080 002	MAR 25, 1994	FEB	WDRP
>D> AB		25MG;250MG	N74080 003	MAR 25, 1994	FEB	WDRP
>A>	@	10MG;100MG	N74080 001	MAR 25, 1994	FEB	WDRP
>A>	@	25MG;100MG	N74080 002	MAR 25, 1994	FEB	WDRP
>A>	@	25MG;250MG	N74080 003	MAR 25, 1994	FEB	WDRP

CASPOFUNGIN ACETATE

INJECTABLE; IV (INFUSION)

CANCIDAS

+	MERCK RES	50MG/VIAL	N21227 001	JAN 26, 2001	JAN	NEWA
+		70MG/VIAL	N21227 002	JAN 26, 2001	JAN	NEWA

CEFACLOR

TABLET, EXTENDED RELEASE; ORAL

CECLOR CD

AB +	LILLY	EQ 500MG BASE	N50673 002	JUN 28, 1996	JAN	CFTG

CEFACLOR

AB	ZENITH GOLDLINE	EQ 500MG BASE	N65057 001	JAN 05, 2001	JAN	NEWA

CEFTAZIDIME
INJECTABLE; INJECTION
TAZICEF

	AP	ABBOTT	500MG/VIAL	N62662 001	MAR 06, 1986	JAN	CAHN
	AP		1GM/VIAL	N62662 002	MAR 06, 1986	JAN	CAHN
	AP		1GM/VIAL	N64032 001	OCT 31, 1993	JAN	CAHN
	AP		2GM/VIAL	N62662 003	MAR 06, 1986	JAN	CAHN
	AP		2GM/VIAL	N64032 002	OCT 31, 1993	JAN	CAHN
	AP		6GM/VIAL	N62662 004	MAR 06, 1986	JAN	CAHN

CEFUROXIME SODIUM
INJECTABLE; INJECTION
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

>A>	+	B BRAUN	EQ 15MG BASE/ML	N50780 001	FEB 21, 2001	FEB	NEWA
>A>	+		EQ 30MG BASE/M	N50780 002	FEB 21, 2001	FEB	NEWA

CHLORAMPHENICOL
SOLUTION/DROPS; OPHTHALMIC
CHLORAMPHENICOL

>D>	AT	AKORN	0.5%	N62042 001	AUG 31, 1981	FEB	WDRP
>A>		@	0.5%	N62042 001	AUG 31, 1981	FEB	WDRP

CHLORDIAZEPOXIDE HYDROCHLORIDE
CAPSULE; ORAL
CHLORDIAZACHEL

>D>	AB	RACHELLE	5MG	N85086 001	MAY 11, 1976	FEB	WDRP
>D>	AB		10MG	N84639 001	MAY 11, 1976	FEB	WDRP
>D>	AB		25MG	N85087 001	MAY 11, 1976	FEB	WDRP
>A>		@	5MG	N85086 001	MAY 11, 1976	FEB	WDRP
>A>		@	10MG	N84639 001	MAY 11, 1976	FEB	WDRP
>A>		@	25MG	N85087 001	MAY 11, 1976	FEB	WDRP

CHLORDIAZEPOXIDE HCL

>D>	AB	FERRANTE	5MG	N85118 001	SEP 02, 1981	FEB	WDRP
>D>	AB		10MG	N85119 001	SEP 02, 1976	FEB	WDRP
>D>	AB		25MG	N85120 001	SEP 02, 1976	FEB	WDRP
>A>		@	5MG	N85118 001	SEP 02, 1981	FEB	WDRP
>A>		@	10MG	N85119 001	SEP 02, 1976	FEB	WDRP
>A>		@	25MG	N85120 001	SEP 02, 1976	FEB	WDRP

CHLORPHENIRAMINE MALEATE
TABLET; ORAL
CHLORPHENIRAMINE MALEATE

>D>	AA	PHARMAVITE	4MG	N85104 001	FEB 11, 1977	FEB	WDRP
>A>		@	4MG	N85104 001	FEB 11, 1977	FEB	WDRP
>D>	AA	WEST WARD	4MG	N83787 001	OCT 18, 1973	FEB	WDRP
>A>		@	4MG	N83787 001	OCT 18, 1973	FEB	WDRP

CIMETIDINE
TABLET; ORAL
CIMETIDINE

	AB	GENEVA PHARMS TECH	200MG	N74506 001	JAN 24, 1996	JAN	CAHN
	AB		300MG	N74506 002	JAN 24, 1996	JAN	CAHN

	AB		400MG	N74506 003	JAN 24, 1996	JAN	CAHN
	AB		800MG	N74506 004	JAN 24, 1996	JAN	CAHN
	CLINDAMYCIN HYDROCHLORIDE						
	CAPSULE; ORAL						
	CLEOCIN HCL						
>A>	AB +	PHARMACIA AND UPJOHN	EQ 300MG BASE	N50162 003	APR 14, 1988	FEB	CFTG
>D>	+		EQ 300MG BASE	N50162 003	APR 14, 1988	FEB	CFTG
	CLINDAMYCIN HCL						
>A>	AB	RANBAXY	EQ 150MG BASE	N65061 001	FEB 02, 2001	FEB	NEWA
>A>	AB		EQ 300MG BASE	N65061 002	FEB 02, 2001	FEB	NEWA
	CLOBETASOL PROPIONATE						
	CREAM; TOPICAL						
	CLOBETASOL PROPIONATE						
>A>	AB1	STIEFEL	0.05%	N75338 001	FEB 09, 2001	FEB	NEWA
	CLORAZEPATE DIPOTASSIUM						
	CAPSULE; ORAL						
	CLORAZEPATE DIPOTASSIUM						
	@ ABLE		3.75MG	N71777 001	JUL 14, 1987	JAN	DISC
	@		7.5MG	N71778 001	JUL 14, 1987	JAN	DISC
	@		15MG	N71779 001	JUL 14, 1987	JAN	DISC
	CROMOLYN SODIUM						
	SOLUTION/DROPS; OPHTHALMIC						
	CROMOLYN SODIUM						
	AT	NOVEX	4%	N75615 001	JAN 26, 2001	JAN	NEWA
	DEXAMETHASONE SODIUM PHOSPHATE						
	INJECTABLE; INJECTION						
	DEXAMETHASONE SODIUM PHOSPHATE						
>D>	AP	DELL LABS	EQ 4MG PHOSPHATE/ML	N83161 001	JUN 06, 1978	FEB	WDRP
>A>		@	EQ 4MG PHOSPHATE/ML	N83161 001	JUN 06, 1978	FEB	WDRP
>D>	SOLUTION/DROPS; OTIC						
>D>	DEXAMETHASONE SODIUM PHOSPHATE						
>D>	AT	AKORN	EQ 0.1% PHOSPHATE	N84855 001	JUN 29, 1976	FEB	WDRP
>A>		@	EQ 0.1% PHOSPHATE	N84855 001	JUN 29, 1976	FEB	WDRP
	DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE						
	OINTMENT; OPHTHALMIC						
	DEXACIDIN						
>D>	AT	CIBA	0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N62566 001	FEB 22, 1985	FEB	CAHN
>A>	AT	NOVARTIS	0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N62566 001	FEB 22, 1985	FEB	CAHN
	SUSPENSION/DROPS; OPHTHALMIC						
>D>	AT	CIBA	0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N62544 001	OCT 29, 1984	FEB	CAHN
>A>	AT		0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N62544 001	OCT 29, 1984	FEB	CAHN
	DEXTROAMPHETAMINE SULFATE						
	TABLET; ORAL						
	DEXTROAMPHETAMINE SULFATE						
	AA	BARR	5MG	N40361 001	JAN 31, 2001	JAN	NEWA
	AA		10MG	N40361 002	JAN 31, 2001	JAN	NEWA

DEXTROAMPHETAMINE SULFATE
TABLET; ORAL
DEXTROSTAT

	AA	+	SHIRE RICHWOOD	10MG	N84051	002	MAY 29, 1975	JAN CFTG

DICLOFENAC POTASSIUM
TABLET; ORAL
DICLOFENAC POTASSIUM

>A>	AB		EON	50MG	N75582	001	FEB 23, 2001	FEB NEWA

DIPHENHYDRAMINE HYDROCHLORIDE
CAPSULE; ORAL
DIPHENHYDRAMINE HCL

>D>	AA		NEWTRON PHARMS	25MG	N86543	001	FEB 08, 1979	FEB WDRP
>D>	AA			50MG	N86544	001	FEB 08, 1979	FEB WDRP
>A>			@	25MG	N86543	001	FEB 08, 1979	FEB WDRP
>A>			@	50MG	N86544	001	FEB 08, 1979	FEB WDRP

DISULFIRAM
TABLET; ORAL
ANTABUSE

			ODYSSEY PHARMS	250MG	N88482	001	DEC 08, 1983	JAN CAHN
		+		500MG	N88483	001	DEC 08, 1983	JAN CAHN

DOXAZOSIN MESYLATE
TABLET; ORAL
DOXAZOSIN MESYLATE

	AB		TEVA	EQ 1MG BASE	N75353	001	JAN 12, 2001	JAN NEWA
	AB			EQ 2MG BASE	N75353	002	JAN 12, 2001	JAN NEWA
	AB			EQ 4MG BASE	N75353	003	JAN 12, 2001	JAN NEWA
	AB			EQ 8MG BASE	N75353	004	JAN 12, 2001	JAN NEWA

DOXYCYCLINE
FOR SUSPENSION; ORAL
DOXYCHEL

>D>	AB		RACHELLE	EQ 25MG BASE/5ML	N61720	001	JUN 18, 1973	FEB WDRP
>A>			@	EQ 25MG BASE/5ML	N61720	001	JUN 18, 1973	FEB WDRP

VIBRAMYCIN

>D>	AB	+	PFIZER	EQ 25MG BASE/5ML	N50006	001	DEC 06, 1967	FEB CTEC
>A>		+		EQ 25MG BASE/5ML	N50006	001	DEC 06, 1967	FEB CTEC

DOXYCYCLINE HYCLATE
INJECTABLE; INJECTION
DOXYCHEL HYCLATE

>D>	AP		RACHELLE	EQ 100MG BASE/VIAL	N61953	001	SEP 10, 1980	FEB WDRP
>A>			@	EQ 100MG BASE/VIAL	N61953	001	SEP 10, 1980	FEB WDRP

TABLET; ORAL
PERIOSTAT

>A>		+	COLLAGENEX PHARMS	20MG	N50783	001	FEB 02, 2001	FEB NEWA

ENALAPRIL MALEATE
TABLET; ORAL
ENALAPRIL MALEATE

	AB	TARO	2.5MG	N75657	001	JAN 23, 2001	JAN NEWA
	AB		5MG	N75657	002	JAN 23, 2001	JAN NEWA
	AB		10MG	N75657	003	JAN 23, 2001	JAN NEWA
	AB		20MG	N75657	004	JAN 23, 2001	JAN NEWA

ENFLURANE
LIQUID; INHALATION
ENFLURANE

>D>	AN	MINRAD	99.9%	N74396	001	JUL 29, 1994	FEB CAHN
>A>	AN		99.9%	N74396	001	JUL 29, 1994	FEB CAHN

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
LIDOCATON

>D>	AP	PHARMATON	0.02MG/ML;2%	N84728	001	AUG 17, 1983	FEB WDRP
>A>		@	0.02MG/ML;2%	N84728	001	AUG 17, 1983	FEB WDRP

ERGOCALCIFEROL
CAPSULE; ORAL
VITAMIN D

>D>	AA	IMPAX LABS	50,000 IU	N80951	001	JUL 13, 1973	FEB DISC
>A>		@	50,000 IU	N80951	001	JUL 13, 1973	FEB DISC

>A> ESOMEPRAZOLE MAGNESIUM
>A> CAPSULE, DELAYED REL PELLETS; ORAL
>A> NEXIUM

>A>	+	ASTRAZENECA	EQ 20MG BASE	N21153	001	FEB 20, 2001	FEB NEWA
>A>	+		EQ 40MG BASE	N21153	002	FEB 20, 2001	FEB NEWA

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE
TABLET; ORAL-28
PREMPRO

	+	WYETH AYERST	0.625MG,0.625MG;2.5MG,2.5MG	N20527	001	NOV 17, 1995	JAN CTNA
	+		0.625MG,0.625MG;5MG,5MG	N20527	003	JAN 09, 1998	JAN CTNA

PREMPRO (PREMARIN;CYCRIN)

	+	WYETH AYERST					
			0.625MG,0.625MG;2.5MG,2.5MG	N20303	001	DEC 30, 1994	JAN CTNA

ESTROPIPATE
TABLET; ORAL
ORTHO-EST

	AB	WOMEN FIRST HLTHCARE	0.75MG	N89567	001	FEB 27, 1991	JAN CAHN
	AB		1.5MG	N89582	001	JUL 17, 1991	JAN CAHN

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE
TABLET; ORAL-28
>A> LOESTRIN FE 1.5/30

>A>	AB +	PARKE DAVIS	0.03MG;1.5MG	N17355	001	APR 30, 1973	FEB CFTG

```
>D>      +                                0.03MG;1.5MG                N17355 001  APR 30, 1973  FEB  CFTG
>A>        LOESTRIN FE 1/20
>A>   AB  +   PARKE DAVIS                 0.02MG;1MG                  N17354 001  APR 30, 1973  FEB  CFTG
>D>      +                                0.02MG;1MG                  N17354 001  APR 30, 1973  FEB  CFTG
>A>        MICROGESTIN FE 1.5/30
>A>   AB      WATSON LABS                0.03MG;1.5MG                N75548 001  FEB 05, 2001  FEB NEWA
>A>        MICROGESTIN FE 1/20
>A>   AB      WATSON LABS                0.02MG;1MG                  N75647 001  FEB 05, 2001  FEB NEWA

       ETHOSUXIMIDE
         SYRUP; ORAL
           ZARONTIN
     AA  +   PARKE DAVIS                  250MG/5ML                   N80258 001  FEB 13, 1974  JAN  CRLD

       ETODOLAC
         TABLET, EXTENDED RELEASE; ORAL
           ETODOLAC
>A>  AB      TEVA                         400MG                       N75665 003  FEB 05, 2001  FEB NEWA

       FAMCICLOVIR
         TABLET; ORAL
           FAMVIR
             NOVARTIS                     125MG                       N20363 003  DEC 11, 1995  JAN  CAHN
                                          250MG                       N20363 001  APR 26, 1996  JAN  CAHN
         +                                500MG                       N20363 002  JUN 29, 1994  JAN  CAHN

       FENTANYL CITRATE
         INJECTABLE; INJECTION
           FENTANYL CITRATE PRESERVATIVE FREE
           @ MARSAM                       EQ 0.05MG BASE/ML           N74917 001  FEB 03, 1998  JAN  DISC

       FLOXURIDINE
         INJECTABLE; INJECTION
           FLOXURIDINE
>A>  AP      AM PHARM PARTNERS            500MG/VIAL                  N75837 001  FEB 22, 2001  FEB NEWA

       FLUOROMETHOLONE
         SUSPENSION; OPHTHALMIC
           FLUOR-OP
>D>  AB      CIBA                         0.1%                        N70185 001  FEB 27, 1986  FEB  CAHN
>A>  AB      NOVARTIS                     0.1%                        N70185 001  FEB 27, 1986  FEB  CAHN

       FLUOXETINE HYDROCHLORIDE
>A>      CAPSULE, DELAYED REL PELLETS; ORAL
>A>        PROZAC WEEKLY
>A>      +   LILLY                        EQ 90MG BASE                N21235 001  FEB 26, 2001  FEB NEWA

       FLUVOXAMINE MALEATE
         TABLET; ORAL
           FLUVOXAMINE MALEATE
     AB      BARR                         25MG                        N75897 001  JAN 25, 2001  JAN NEWA
     AB                                   50MG                        N75897 002  JAN 25, 2001  JAN NEWA
     AB                                   100MG                       N75897 003  JAN 25, 2001  JAN NEWA
```

	AB	INVAMED	25MG	N75887 001	JAN 05, 2001	JAN	NEWA
	AB		50MG	N75887 002	JAN 05, 2001	JAN	NEWA
	AB		100MG	N75887 003	JAN 05, 2001	JAN	NEWA
	AB	SYNTHON PHARMS	25MG	N75899 001	JAN 17, 2001	JAN	NEWA
	AB		50MG	N75899 002	JAN 17, 2001	JAN	NEWA
	AB		100MG	N75899 003	JAN 17, 2001	JAN	NEWA
>A>		FORMOTEROL FUMARATE					
>A>		CAPSULE; INHALATION					
>A>		FORADIL					
>A>	+	NOVARTIS	0.012MG/INH	N20831 001	FEB 16, 2001	FEB	NEWA
>A>		GALANTAMINE HYDROBROMIDE					
>A>		TABLET; ORAL					
>A>		REMINYL					
>A>		JANSSEN RES FDN	EQ 4MG BASE	N21169 001	FEB 28, 2001	FEB	NEWA
>A>			EQ 8MG BASE	N21169 002	FEB 28, 2001	FEB	NEWA
>A>	+		EQ 12MG BASE	N21169 003	FEB 28, 2001	FEB	NEWA
		GEMFIBROZIL					
		TABLET; ORAL					
		GEMFIBROZIL					
	AB	GENEVA PHARMS TECH	600MG	N74615 001	SEP 29, 1995	JAN	CAHN
		GENTAMICIN SULFATE					
		INJECTABLE; INJECTION					
>D>		U-GENCIN					
>D>	AP	PHARMACIA AND UPJOHN	EQ 10MG BASE/ML	N62248 001	MAY 02, 1980	FEB	WDRP
>D>	AP		EQ 40MG BASE/ML	N62248 002	MAY 02, 1980	FEB	WDRP
>A>		@	EQ 10MG BASE/ML	N62248 001	MAY 02, 1980	FEB	WDRP
>A>		@	EQ 40MG BASE/ML	N62248 002	MAY 02, 1980	FEB	WDRP
		OINTMENT; OPHTHALMIC					
		GENTACIDIN					
>D>	AT	CIBA	EQ 0.3% BASE	N62501 001	JUL 26, 1984	FEB	CAHN
>A>	AT	NOVARTIS	EQ 0.3% BASE	N62501 001	JUL 26, 1984	FEB	CAHN
		SOLUTION/DROPS; OPHTHALMIC					
		GENTACIDIN					
>D>	AT	CIBA	EQ 0.3% BASE	N62480 001	MAR 30, 1984	FEB	CAHN
>A>	AT	NOVARTIS	EQ 0.3% BASE	N62480 001	MAR 30, 1984	FEB	CAHN
		GLIPIZIDE					
		TABLET; ORAL					
		GLIPIZIDE					
	AB	GENEVA PHARMS TECH	5MG	N74542 001	JUN 20, 1995	JAN	CAHN
	AB		10MG	N74542 002	JUN 20, 1995	JAN	CAHN
		HALOTHANE					
		LIQUID; INHALATION					
		HALOTHANE					
		@ BH	99.99%	N84977 001	JUL 14, 1976	JAN	DISC

HEPARIN SODIUM
INJECTABLE; INJECTION
HEPARIN SODIUM PRESERVATIVE FREE

>D>	AP	PHARMA SERVE NY	1,000 UNITS/ML	N86129 001	FEB 22, 1980	FEB	WDRP
>A>		@	1,000 UNITS/ML	N86129 001	FEB 22, 1980	FEB	WDRP

HYDROCHLOROTHIAZIDE; RESERPINE
TABLET; ORAL
RESERPINE AND HYDROCHLOROTHIAZIDE-50

>D>	BP	WEST WARD	50MG;0.125MG	N88189 001	MAY 10, 1984	FEB	WDRP
>A>		@	50MG;0.125MG	N88189 001	MAY 10, 1984	FEB	WDRP

HYDROCORTISONE
CREAM; TOPICAL
HC (HYDROCORTISONE)

>D>	AT	C AND M PHARMA	0.5%	N80482 003	MAR 20, 1973	FEB	WDRP
>D>	AT		1%	N80482 004	MAR 20, 1973	FEB	WDRP
>A>		@	0.5%	N80482 003	MAR 20, 1973	FEB	WDRP
>A>		@	1%	N80482 004	MAR 20, 1973	FEB	WDRP

HYDROCORTISONE

>D>	AT	TOPIDERM	1%	N89273 001	FEB 17, 1989	FEB	WDRP
>A>		@	1%	N89273 001	FEB 17, 1989	FEB	WDRP

PROCTOCORT

>D>	AT	MONARCH PHARMS	1%	N83011 001	APR 26, 1973	FEB	DISC
>A>		@	1%	N83011 001	APR 26, 1973	FEB	DISC

LOTION; TOPICAL
BETA-HC

>D>	AT	BETA DERMAC	1%	N89495 001	JAN 25, 1988	FEB	WDRP
>A>		@	1%	N89495 001	JAN 25, 1988	FEB	WDRP

GLYCORT

>D>	AT	HERAN	1%	N87489 001	OCT 03, 1983	FEB	WDRP
>A>		@	1%	N87489 001	OCT 03, 1983	FEB	WDRP

OINTMENT; TOPICAL
HC (HYDROCORTISONE)

>D>	AT	C AND M PHARMA	1%	N80481 002	MAR 20, 1973	FEB	WDRP
>A>		@	1%	N80481 002	MAR 20, 1973	FEB	WDRP

POWDER; FOR RX COMPOUNDING
H-CORT

>D>	AA	TORCH	100%	N87834 001	MAR 29, 1982	FEB	WDRP
>A>		@	100%	N87834 001	MAR 29, 1982	FEB	WDRP

HYDROCORTISONE ACETATE
CREAM; TOPICAL
MICORT-HC

>A>		FERNDALE LABS	2.5%	N40396 001	FEB 27, 2001	FEB	NEWA

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE
SUSPENSION/DROPS; OPHTHALMIC
COR-OTICIN

>D>	+	AKORN	1.5%;EQ 3.5MG BASE/ML	N60188 001	OCT 26, 1968	FEB	WDRP
>A>		@	1.5%;EQ 3.5MG BASE/ML	N60188 001	OCT 26, 1968	FEB	WDRP

HYDROXYZINE PAMOATE
CAPSULE; ORAL
HYDROXYZINE PAMOATE

>D>	AB	VANGARD	EQ 50MG HCL	N88393 001	SEP 19, 1983	FEB	WDRP
>A>		@	EQ 50MG HCL	N88393 001	SEP 19, 1983	FEB	WDRP

INDAPAMIDE
TABLET; ORAL
INDAPAMIDE

	AB	GENEVA PHARMS TECH	1.25MG	N74594 001	MAY 23, 1996	JAN	CAHN
	AB		2.5MG	N74594 002	MAY 23, 1996	JAN	CAHN

IPRATROPIUM BROMIDE
SOLUTION; INHALATION
IPRATROPIUM BROMIDE

	AN	ASLUNG PHARM	0.02%	N75693 001	JAN 26, 2001	JAN	NEWA
	AN	WARRICK PHARMS	0.02%	N75507 001	JAN 19, 2001	JAN	NEWA

ISOFLURANE
LIQUID; INHALATION
ISOFLURANE

>D>	AN	MINRAD	99.9%	N74416 001	SEP 30, 1994	FEB	CAHN
>A>	AN		99.9%	N74416 001	SEP 30, 1994	FEB	CAHN

LEUCOVORIN CALCIUM
INJECTABLE; INJECTION
LEUCOVORIN CALCIUM PRESERVATIVE FREE

	AP	LUITPOLD	EQ 50MG BASE/VIAL	N40338 001	JAN 31, 2001	JAN	NEWA

LIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
LIDOCATON

>D>	AP	PHARMATON	2%	N84727 001	AUG 17, 1983	FEB	WDRP
>A>		@	2%	N84727 001	AUG 17, 1983	FEB	WDRP

MEPROBAMATE
TABLET; ORAL
AMOSENE

>D>	AA	FERNDALE LABS	400MG	N84030 001	MAY 10, 1974	FEB	WDRP
>A>			400MG	N84030 001	MAY 10, 1974	FEB	WDRP

MESALAMINE
SUPPOSITORY; RECTAL
CANASA

	+	AXCAN SCANDIPHARM	500MG	N21252 001	JAN 05, 2001	JAN	NEWA

METAPROTERENOL SULFATE
SOLUTION; INHALATION
METAPROTERENOL SULFATE

>A>	AN	NOVEX	0.4%	N75402 001	FEB 28, 2001	FEB	NEWA
>A>	AN		0.6%	N75403 001	FEB 28, 2001	FEB	NEWA

METHYLPHENIDATE HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL
METHYLPHENIDATE HCL

>A>	AB	DANBURY PHARMA	20MG	N40410 001	FEB 09, 2001	FEB	NEWA

METHYLTESTOSTERONE
TABLET; BUCCAL
ORETON

>D>	+	SCHERING	10MG	N80281 001	AUG 03, 1979	FEB	DISC
>A>	@		10MG	N80281 001	AUG 03, 1979	FEB	DISC

METOCLOPRAMIDE HYDROCHLORIDE
SOLUTION; INJECTION
METOCLOPRAMIDE

AA	UDL	EQ 5MG BASE/5ML	N75051 001	JAN 26, 2001	JAN	NEWA

TABLET; ORAL
METOCLOPRAMIDE HCL

AB	GENEVA PHARMS TECH	EQ 5MG BASE	N74478 001	OCT 05, 1995	JAN	CAHN
AB		EQ 10MG BASE	N74478 002	OCT 05, 1995	JAN	CAHN

METOPROLOL SUCCINATE
TABLET, EXTENDED RELEASE; ORAL
TOPROL-XL

>A>	+	ASTRAZENECA	EQ 25MG TARTRATE	N19962 004	FEB 05, 2001	FEB	NEWA

MINOCYCLINE HYDROCHLORIDE
>A> POWDER, EXTENDED RELEASE; DENTAL
>A> ARESTIN

>A>	+		EQ 1MG BASE	N50781 001	FEB 16, 2001	FEB	NEWA

MIRTAZAPINE
TABLET, ORALLY DISINTEGRATING; ORAL
REMERON SOLTAB

+	ORGANON INC	15MG	N21208 001	JAN 12, 2001	JAN	NEWA
		30MG	N21208 002	JAN 12, 2001	JAN	NEWA
		45MG	N21208 003	JAN 12, 2001	JAN	NEWA

MORPHINE SULFATE
TABLET, EXTENDED RELEASE; ORAL
MORPHINE SULFATE

AB	WATSON LABS	100MG	N75656 001	JAN 30, 2001	JAN	NEWA

NADOLOL
TABLET; ORAL
NADOLOL

AB	GENEVA PHARMS TECH	20MG	N74501 001	NOV 09, 1995	JAN	CAHN
AB		40MG	N74501 002	NOV 09, 1995	JAN	CAHN
AB		80MG	N74501 003	NOV 09, 1995	JAN	CAHN

NALOXONE HYDROCHLORIDE
INJECTABLE; INJECTION
NALOXONE

		@ WYETH AYERST	0.02MG/ML	N70188 001	SEP 24, 1986	JAN	DISC
		@	0.02MG/ML	N70189 001	SEP 24, 1986	JAN	DISC
		@	0.4MG/ML	N70190 001	SEP 24, 1986	JAN	DISC
		@	0.4MG/ML	N70191 001	SEP 24, 1986	JAN	DISC

NAPHAZOLINE HYDROCHLORIDE
SOLUTION/DROPS; OPHTHALMIC
VASOCON

>D>	AT	CIBA	0.1%	N80235 002	MAR 24, 1983	FEB	CAHN
>A>	AT	NOVARTIS	0.1%	N80235 002	MAR 24, 1983	FEB	CAHN

NAPROXEN SODIUM
TABLET; ORAL
NAPROXEN SODIUM

	AB	GENEVA PHARMS TECH	EQ 250MG BASE	N74495 001	DEC 05, 1994	JAN	CAHN
	AB		EQ 500MG BASE	N74495 002	DEC 05, 1994	JAN	CAHN

NIFEDIPINE
CAPSULE; ORAL
NIFEDIPINE

>D>	AB	CHASE LABS NJ	10MG	N72409 001	JUL 04, 1990	FEB	WDRP
>D>	AB		20MG	N73421 001	JUN 19, 1991	FEB	WDRP
>A>		@	10MG	N72409 001	JUL 04, 1990	FEB	WDRP
>A>		@	20MG	N73421 001	JUN 19, 1991	FEB	WDRP

TABLET, EXTENDED RELEASE; ORAL

>A>	AB2	BIOVAIL	30MG	N75289 002	FEB 06, 2001	FEB	NEWA

PROCARDIA XL

>A>	AB2 +	PFIZER	30MG	N19684 001	SEP 06, 1989	FEB	CTEC
>D>	BC +		30MG	N19684 001	SEP 06, 1989	FEB	CTEC

NITROFURAZONE
POWDER; TOPICAL
FURACIN

>D>		ROBERTS LABS	0.2%	N83791 001	OCT 17, 1975	FEB	WDRP
>A>		@	0.2%	N83791 001	OCT 17, 1975	FEB	WDRP

NYSTATIN
TABLET; VAGINAL
KOROSTATIN

>D>	AT	HOLLAND RANTOS	100,000 UNITS	N61718 001	SEP 30, 1974	FEB	WDRP
>A>		@	100,000 UNITS	N61718 001	SEP 30, 1974	FEB	WDRP

OXACILLIN SODIUM
INJECTABLE; INJECTION
BACTOCILL

>D>	AP +	SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL	N62736 001	DEC 19, 1986	FEB	DISC
>D>	AP +		EQ 2GM BASE/VIAL	N62736 002	DEC 19, 1986	FEB	DISC
>A>		@	EQ 1GM BASE/VIAL	N62736 001	DEC 19, 1986	FEB	DISC
>A>		@	EQ 2GM BASE/VIAL	N62736 002	DEC 19, 1986	FEB	DISC

OXACILLIN SODIUM
INJECTABLE; INJECTION
OXACILLIN SODIUM

>D>	AP		APOTHECON	EQ 1GM BASE/VIAL	N61490 003	APR 08, 1971	FEB	CRLD
>A>	AP	+		EQ 1GM BASE/VIAL	N61490 003	APR 08, 1971	FEB	CRLD
>D>	AP			EQ 2GM BASE/VIAL	N62737 002	DEC 23, 1986	FEB	CRLD
>A>	AP	+		EQ 2GM BASE/VIAL	N62737 002	DEC 23, 1986	FEB	CRLD

OXAPROZIN
TABLET; ORAL
DAYPRO

	AB	+	SEARLE	600MG	N18841 004	OCT 29, 1992	JAN	CFTG

OXAPROZIN

	AB		DR REDDYS LABS LTD	600MG	N75855 001	JAN 31, 2001	JAN	NEWA
	AB		EON	600MG	N75845 001	JAN 31, 2001	JAN	NEWA
>A>	AB		GENPHARM	600MG	N75847 001	FEB 28, 2001	FEB	NEWA
>A>	AB		WATSON LABS	600MG	N75848 001	FEB 09, 2001	FEB	NEWA

OXYTETRACYCLINE HYDROCHLORIDE
CAPSULE; ORAL
OXYTETRACYCLINE HCL

>D>	AB		IMPAX LABS	EQ 250MG BASE	N60760 001	AUG 09, 1967	FEB	DISC
>A>			@	EQ 250MG BASE	N60760 001	AUG 09, 1967	FEB	DISC
>D>	AB		PROTER	EQ 250MG BASE	N60869 001	JAN 29, 1964	FEB	WDRP
>A>			@	EQ 250MG BASE	N60869 001	JAN 29, 1964	FEB	WDRP

PENICILLIN G SODIUM
INJECTABLE; IM-IV
PENICILLIN G SODIUM

>A>		+	BIOCHEMIE	5,000,000 UNITS/VIALS	N65068 001	FEB 26, 2001	FEB	NEWA
>D>		+	MARSAM	5,000,000 UNITS/VIALS	N63014 001	SEP 13, 1988	FEB	DISC
>A>			@	5,000,000 UNITS/VIALS	N63014 001	SEP 13, 1988	FEB	DISC

PHENYTOIN
SUSPENSION; ORAL
PHENYTOIN

	AB		UDL	125MG/5ML	N40342 001	JAN 31, 2001	JAN	NEWA

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM
OINTMENT; OPHTHALMIC
VASOCIDIN

>D>	AT		CIBA	0.5%;10%	N88791 001	OCT 05, 1984	FEB	CAHN
>A>	AT		NOVARTIS	0.5%;10%	N88791 001	OCT 05, 1984	FEB	CAHN

SUSPENSION/DROPS; OPHTHALMIC
METIMYD

>D>	AT	+	SCHERING	0.5%;10%	N10210 001	FEB 24, 1956	FEB	CTEC
>A>		+		0.5%;10%	N10210 001	FEB 24, 1956	FEB	CTEC

PREDAMIDE

>D>	AT		AKORN	0.5%;10%	N88059 001	JUL 29, 1983	FEB	WDRP
>A>			@	0.5%;10%	N88059 001	JUL 29, 1983	FEB	WDRP

SULPHRIN

>D>	AT		BAUSCH AND LOMB	0.5%;10%	N88089 001	DEC 28, 1982	FEB	WDRP
>A>			@	0.5%;10%	N88089 001	DEC 28, 1982	FEB	WDRP

PREDNISOLONE SODIUM PHOSPHATE
SOLUTION/DROPS; OPHTHALMIC
INFLAMASE FORTE

>D>	AT	+	CIBA	EQ 0.9% PHOSPHATE	N80751	002	DEC 19, 1973	FEB	CAHN
>A>	AT	+	NOVARTIS	EQ 0.9% PHOSPHATE	N80751	002	DEC 19, 1973	FEB	CAHN

INFLAMASE MILD

>D>	AT	+	CIBA	EQ 0.11% PHOSPHATE	N80751	001	DEC 19, 1973	FEB	CAHN
>A>	AT	+	NOVARTIS	EQ 0.11% PHOSPHATE	N80751	001	DEC 19, 1973	FEB	CAHN

PREDNISOLONE SODIUM PHOSPHATE

>D>	AT		AKORN	EQ 0.11% PHOSPHATE	N83358	001	AUG 21, 1974	FEB	WDRP
>D>	AT			EQ 0.9% PHOSPHATE	N83358	002	AUG 21, 1974	FEB	WDRP
>A>			@	EQ 0.11% PHOSPHATE	N83358	001	AUG 21, 1974	FEB	WDRP
>A>			@	EQ 0.9% PHOSPHATE	N83358	002	AUG 21, 1974	FEB	WDRP

PROCHLORPERAZINE MALEATE
TABLET; ORAL
PROCHLORPERAZINE MALEATE

	AB		GENEVA PHARMS TECH	EQ 5MG BASE	N40101	001	JUL 19, 1996	JAN	CAHN
	AB			EQ 10MG BASE	N40101	002	JUL 19, 1996	JAN	CAHN
	AB			EQ 25MG BASE	N40101	003	JUL 19, 1996	JAN	CAHN

PROTRIPTYLINE HYDROCHLORIDE
TABLET; ORAL
PROTRIPTYLINE HCL

	AB		ODYSSEY PHARMS	5MG	N73644	001	AUG 24, 1995	JAN	CAHN
	AB			10MG	N73645	001	AUG 24, 1995	JAN	CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE
SYRUP; ORAL
TRILITRON

>D>		+	NEWTRON PHARMS	30MG/5ML;1.25MG/5ML	N88474	001	FEB 12, 1985	FEB	WDRP
>A>			@	30MG/5ML;1.25MG/5ML	N88474	001	FEB 12, 1985	FEB	WDRP

QUINIDINE SULFATE
TABLET; ORAL
QUINIDINE SULFATE

>D>	AB		IMPAX LABS	200MG	N83347	001	DEC 08, 1976	FEB	DISC
>A>			@	200MG	N83347	001	DEC 08, 1976	FEB	DISC

SECOBARBITAL SODIUM
CAPSULE; ORAL
SECOBARBITAL SODIUM

>D>	AA		ICN	100MG	N85477	001	DEC 10, 1981	FEB	WDRP
>A>			@	100MG	N85477	001	DEC 10, 1981	FEB	WDRP

SULFACETAMIDE SODIUM
SOLUTION/DROPS; OPHTHALMIC
SULF-10

>D>			@ CIBA	10%	N80025	001	JUN 03, 1971	FEB	CAHN
>A>			@ NOVARTIS	10%	N80025	001	JUN 03, 1971	FEB	CAHN

SULF-15

>D>	AT		CIBA	15%	N89047	001	OCT 31, 1995	FEB	CAHN

>A>	AT	NOVARTIS	15%	N89047 001	OCT 31, 1995	FEB	CAHN
>D>		SULTEN-10					
>D>	AT	BAUSCH AND LOMB	10%	N87818 001	FEB 03, 1983	FEB	WDRP
>A>		@	10%	N87818 001	FEB 03, 1983	FEB	WDRP
		SULFAMETHOXAZOLE; TRIMETHOPRIM					
		SUSPENSION; ORAL					
>D>		TRIMETH/SULFA					
>D>	AB	NASKA	200MG/5ML;40MG/5ML	N72399 001	MAY 23, 1988	FEB	WDRP
>A>		@	200MG/5ML;40MG/5ML	N72399 001	MAY 23, 1988	FEB	WDRP
		SULFANILAMIDE					
		CREAM; VAGINAL					
		AVC					
	AT +	NOVAVAX	15%	N06530 003	JAN 27, 1987	JAN	CAHN
		SUPPOSITORY; VAGINAL					
	+	NOVAVAX	1.05GM	N06530 004	JAN 27, 1987	JAN	CAHN
		TERAZOSIN HYDROCHLORIDE					
		CAPSULE; ORAL					
		TERAZOSIN HCL					
	AB	ZENITH GOLDLINE	EQ 1MG BASE	N75614 002	JAN 30, 2001	JAN	NEWA
	AB		EQ 2MG BASE	N75614 001	JAN 30, 2001	JAN	NEWA
	AB		EQ 5MG BASE	N75614 003	JAN 30, 2001	JAN	NEWA
	AB		EQ 10MG BASE	N75614 004	JAN 30, 2001	JAN	NEWA
		THYROGLOBULIN					
>D>		TABLET; ORAL					
>D>		THYROGLOBULIN					
>D>	+	IMPAX LABS	64.8MG	N80151 001	AUG 07, 1973	FEB	DISC
>A>		@	64.8MG	N80151 001	AUG 07, 1973	FEB	DISC
		TRIAMCINOLONE					
		TABLET; ORAL					
		TRIAMCINOLONE					
>D>	BP	IMPAX LABS	4MG	N84340 001	APR 22, 1975	FEB	DISC
>A>		@	4MG	N84340 001	APR 22, 1975	FEB	DISC
		TRIAMCINOLONE ACETONIDE					
		CREAM; TOPICAL					
		TRIAMCINOLONE ACETONIDE					
>D>	AT	TOPIDERM	0.025%	N89274 001	FEB 21, 1989	FEB	WDRP
>D>	AT		0.1%	N89275 001	FEB 21, 1989	FEB	WDRP
>D>	AT		0.5%	N89276 001	FEB 21, 1989	FEB	WDRP
>A>		@	0.025%	N89274 001	FEB 21, 1989	FEB	WDRP
>A>		@	0.1%	N89275 001	FEB 21, 1989	FEB	WDRP
>A>		@	0.5%	N89276 001	FEB 21, 1989	FEB	WDRP
		TRICHLORMETHIAZIDE					
		TABLET; ORAL					
		TRICHLOREX					
>D>	BP	LANNETT	4MG	N85630 001	MAY 16, 1977	FEB	WDRP
>A>		@	4MG	N85630 001	MAY 16, 1977	FEB	WDRP

TRIFLUOPERAZINE HYDROCHLORIDE
TABLET; ORAL
TRIFLUOPERAZINE HCL

AB	GENEVA PHARMS TECH	EQ 1MG BASE	N40153	001	OCT 25, 1996	JAN	CAHN
AB		EQ 2MG BASE	N40153	002	OCT 25, 1996	JAN	CAHN
AB		EQ 5MG BASE	N40153	003	OCT 25, 1996	JAN	CAHN
AB		EQ 10MG BASE	N40153	004	OCT 25, 1996	JAN	CAHN

VITAMIN A PALMITATE
CAPSULE; ORAL
VITAMIN A

>D> AA	WEST WARD	EQ 50,000 UNITS BASE	N80967	001	MAY 04, 1973	FEB	WDRP
>A>	@	EQ 50,000 UNTIS BASE	N80967	001	MAY 04, 1973	FEB	WDRP

>A> ZIPRASIDONE HYDROCHLORIDE
>A> CAPSULE; ORAL
>A> GEODON

>A>	PFIZER	20MG	N20825	001	FEB 05, 2001	FEB	NEWA
>A>		40MG	N20825	002	FEB 05, 2001	FEB	NEWA
>A>		60MG	N20825	003	FEB 05, 2001	FEB	NEWA
>A> +		80MG	N20825	004	FEB 05, 2001	FEB	NEWA

ZOLMITRIPTAN
>A> TABLET, ORALLY DISINTEGRATING; ORAL
>A> ZOMIG-ZMT

>A>	ASTRAZENECA	2.5MG	N21231	001	FEB 13, 2001	FEB	NEWA

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TAVIST-D

@ NOVARTIS	1.34MG;75MG	N18298 002	AUG 21, 1992	JAN	DISC
@	1.34MG;75MG	N20640 001	AUG 09, 1996	JAN	DISC

MICONAZOLE NITRATE

>A> CREAM; TOPICAL, VAGINAL

>A> MONISTAT 3 COMBINATION PACK

>A> + PERSONAL PRODS	2%,4%	N21261 001	FEB 02, 2001	FEB	NEWA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 2 FEBRUARY '01

NO FEBRUARY 2001 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Products Designations and Approvals List
February 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Alendronate disodium TN=Fosamax	Treatment of the bone manifestations of Gaucher disease	Richard J. Wenstrup, M.D. Division of Human Genetics Children's Hospital Research Cincinnati OH 45229-3039 DD= 2/13/01 MA=
B Lymphocyte Stimulator TN=BLyS	Treatment of common variable immunodeficiency (CVID)	Human Genome Sciences, Inc. 9410 Key West Avenue Rockville MD 20850 DD= 2/21/01 MA=
Imatinib TN=Glivec	Treatment of chronic myelogenous leukemia	Novartis Pharmaceuticals 59 Route 10 East Hanover NJ 07936-1080 DD= 1/31/01 MA=
Medroxyprogesterone acetate TN=Hematrol	Treatment of immune thrombocytopenic purpura.	InKine Pharmaceutical Company, 1787 Sentry Parkway West Building 18, Suite 440 Blue Bell PA 19422 DD= 2/22/01 MA=
MTC-DOX for Injection TN=	Treatment of hepatocellular carcinoma	FeRx Incorporated 4330 La Jolla Village Drive Suite #250 San Diego CA 92122 DD= 1/3/01 MA=

Orphan Products Designations and Approvals List
Febuary 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Nitroprusside TN=	Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.	Thomas, MD, Jeffrey Evan Thomas Jefferson University and 834 Walnut Street, Suite 650 Philadelphia PA 19107-5102 DD= 2/21/01 MA=
Novel Acting Thrombolytic (NAT) TN=	Treatment of peripheral arterial occlusion (PAO)	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799 DD= 1/26/01 MA=
Polyethylene glycol (PEG)-uricase TN=	To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.	Bio-Technology General Corporation 70 Wood Avenue South Iselin NJ 08830 DD= 2/21/01 MA=
Pyruvate TN=	Treatment of interstitial lung disease.	Cellular Sciences, Inc 84 park Avenue P.O. Box 968 Flemington NJ 08822 DD= 2/21/01 MA=
Recombinant Human Alpha-Fetoprotein TN=	Treatment of myasthenia gravis	Atlantic Biopharmaceuticals, Inc. 50 Church Street 5th floor Cambridge MA 02138 DD= 2/22/01 MA=
Synthetic Human Parathyroid Hormone 1-34 TN=	Treatment of hypoparathyroidism	Orphan Pharmaceuticals, U.S., Inc. 1101 Kermit Drive, Suite 608 Nashville TN 37217 DD= 1/26/01 MA=

Orphan Products Designations and Approvals List
Febuary 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Virulizin TN=Virulizin	Treatment of pancreatic cancer.	Lorus Therapeutics Inc. 7100 Woodbine Avenue, Suite 215 Markham, ON L3R 5J2 Canada DD= 2/1/01 MA=

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO FEBRUARY 2001 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021205 001	ABACAVIR SULFATE;TRIZIVIR	6180639	JAN 30, 2018	U-248		
	021082 001	ACETAMINOPHEN;TAVIST ALLERGY/SINUS				NC	MAR 01, 2004
	020760 001	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6194429	JUL 23, 2018			
	020760 002	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6194429	JUL 23, 2018		NCE	DEC 18, 2002
>ADD>	020950 001	ALBUTEROL SULFATE;DUOVENT				NP	MAR 21, 2004
>ADD>	020983 001	ALBUTEROL SULFATE;VENTOLIN HFA				I-235	SEP 23, 2001
>ADD>						I-262	JUN 02, 2002
	020560 001	ALENDRONATE SODIUM;FOSAMAX	6194004	DEC 02, 2012			
	021107 001	ALOSETRON HYDROCHLORIDE;LOTRONEX	5360800	FEB 02, 2010			
	021078 001	ATOVAQUONE;MALARONE	6166046	NOV 25, 2013		NC	JUL 14, 2003
			5053432	OCT 01, 2008			
	021078 002	ATOVAQUONE;MALARONE PEDIATRIC	5053432	OCT 01, 2008		NC	JUL 14, 2003
>ADD>	021275 001	BIMATOPROST;LUMIGAN	5688819	SEP 21, 2012		NCE	MAR 16, 2006
>ADD>	021262 001	BRIMONIDINE TARTRATE;ALPHAGAN P				NP	MAY 16, 2004
>ADD>	074253 001	BUSPIRONE HYDROCHLORIDE;BUSPIRONE				PC	SEP 26, 2001
>ADD>	074253 002	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
>ADD>	075272 003	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 24, 2001
>ADD>	075467 002	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
	018874 001	CALCITRIOL;CALCIJEX	4308264	JAN 28, 2001			
			6051567	AUG 02, 2019			
			4308264*PED	JUL 28, 2001			
			6051567*PED	FEB 02, 2020			
	018874 002	CALCITRIOL;CALCIJEX	4308264	JAN 28, 2001			
			6051567	AUG 02, 2019			
			4308264*PED	JUL 28, 2001			
			6051567*PED	FEB 02, 2020			
>ADD>	019976 001	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
>ADD>	021160 001	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
>ADD>	021160 002	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
>ADD>	021160 003	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
>ADD>	020896 001	CAPECITABINE;XELODA				I-323	APR 30, 2004
>ADD>	020896 002	CAPECITABINE;XELODA				I-323	APR 30, 2004
>ADD>	021227 001	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017		NCE	JAN 26, 2006
>ADD>			5378804	MAR 16, 2013			
>ADD>			5514650	MAR 16, 2013			
>ADD>			5792746	MAR 16, 2013			
>ADD>			6136783	MAR 28, 2017			
>ADD>	021227 002	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017		NCE	JAN 26, 2006
>ADD>			5378804	MAR 16, 2013			
>ADD>			5514650	MAR 16, 2013			
>ADD>			5792746	MAR 16, 2013			
>ADD>			6136783	MAR 28, 2017			
>ADD>	019111 001	CHLORPHENIRAMINE POLISTIREX;TUSSIONEX	4762709	AUG 09, 2005			
>ADD>	021022 001	CICLOPIROX;PENLAC	4957730	SEP 18, 2007	U-379		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020705 001	DELAVIRDINE MESYLATE;RESCRIPTOR	6177101	JUN 11, 2018			
	021005 001	DICLOFENAC SODIUM;SOLARAZE				NP	OCT 16, 2003
>ADD>	020154 002	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
			5254539	AUG 29, 2006	U-248		
>ADD>			5880106	JUL 22, 2011			
>ADD>	020154 003	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
>ADD>			5254539	AUG 29, 2006	U-248		
>ADD>			5880106	JUL 22, 2011			
>ADD>	020154 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
>ADD>			5254539	AUG 29, 2006	U-248		
>ADD>			5880106	JUL 22, 2011			
>ADD>	020154 005	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
>ADD>			5254539	AUG 29, 2006	U-248		
>ADD>			5880106	JUL 22, 2011			
>ADD>	020154 006	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
>ADD>			5254539	AUG 29, 2006	U-248		
>ADD>			5880106	JUL 22, 2011			
>ADD>	020155 003	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
>ADD>			5254539	AUG 29, 2006	U-248		
>ADD>	020155 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
>ADD>			5254539	AUG 29, 2006	U-248		
>ADD>	020155 005	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
>ADD>			5254539	AUG 29, 2006	U-248		
>ADD>	020156 001	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
>ADD>			5254539	AUG 29, 2006	U-248		
>ADD>	021183 001	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248		
>ADD>			5254539	AUG 29, 2006	U-248		
>ADD>	021183 002	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248		
>ADD>			5254539	AUG 29, 2006	U-248		
>ADD>	021183 003	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248		
>ADD>			5254539	AUG 29, 2006	U-248		
>ADD>	021183 004	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248		
>ADD>			5254539	AUG 29, 2006	U-248		
>ADD>	020623 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
>ADD>	020623 002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
>ADD>	020624 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
>ADD>	018998 001	ENALAPRIL MALEATE;VASOTEC				M-7	DEC 13, 2004
>ADD>	018998 002	ENALAPRIL MALEATE;VASOTEC				M-7	DEC 13, 2004
>ADD>	018998 003	ENALAPRIL MALEATE;VASOTEC				M-7	DEC 13, 2004
>ADD>	018998 005	ENALAPRIL MALEATE;VASOTEC				M-7	DEC 13, 2004
	020164 002	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 003	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020164 004	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 005	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 006	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001			
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 007	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 008	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
>ADD>	021153 001	ESOMEPRAZOLE MAGNESIUM;NEXIUM	6147103	OCT 09, 2018		NP	FEB 20, 2004
>ADD>			6166213	OCT 09, 2018			
>ADD>			6191148	OCT 09, 2018			
			4255431	APR 05, 2001	U-373		
			4738974	APR 19, 2005	U-373		
			4636499	MAY 30, 2005	U-373		
			5900424	MAY 04, 2016	U-373		
			4786505	APR 20, 2007	U-373		
			4853230	APR 20, 2007	U-373		
			5714504	FEB 03, 2015	U-373		
			5877192	MAY 27, 2014	U-373		
			5093342	FEB 02, 2010	U-373		
			5599794	FEB 04, 2014	U-373		
			5629305	FEB 04, 2014	U-373		
			5690960	NOV 25, 2014	U-373		
>ADD>	021153 002	ESOMEPRAZOLE MAGNESIUM;NEXIUM	6147103	OCT 09, 2018		NP	FEB 20, 2004
>ADD>			6166213	OCT 09, 2018			
>ADD>			6191148	OCT 09, 2018			
			4255431	APR 05, 2001	U-373		
			4738974	APR 19, 2005	U-373		
			4636499	MAY 30, 2005	U-373		
			5900424	MAY 04, 2016	U-373		
			4786505	APR 20, 2007	U-373		
			4853230	APR 20, 2007	U-373		
			5714504	FEB 03, 2015	U-373		
			5877192	MAY 27, 2014	U-373		
			5093342	FEB 02, 2010	U-373		
			5599794	FEB 04, 2014	U-373		
			5629305	FEB 04, 2014	U-373		
			5690960	NOV 25, 2014	U-373		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020538 005	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
			5474783	DEC 12, 2012			
			5656286	AUG 12, 2014			
			5958446	DEC 12, 2012			
	020538 006	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
			5474783	DEC 12, 2012			
			5656286	AUG 12, 2014			
			5958446	DEC 12, 2012			
	020538 007	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
			5474783	DEC 12, 2012			
			5656286	AUG 12, 2014			
			5958446	DEC 12, 2012			
	020538 008	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
			5474783	DEC 12, 2012			
			5656286	AUG 12, 2014			
			5958446	DEC 12, 2012			
	020946 001	ETHINYL ESTRADIOL;PREVEN EMERGENCY CON	6156742	DEC 05, 2020	U-374		
	020584 001	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
	020584 002	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
	020584 003	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
	021235 001	FLUOXETINE HYDROCHLORIDE;PROZAC WEEKLY				NDF	FEB 26, 2004
>ADD>	018936 007	FLUOXETINE HYDROCHLORIDE;SARAFEM				PED	JAN 06, 2004
	020831 001	FORMOTEROL FUMARATE;FORADIL				NCE	FEB 16, 2006
	021169 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
	021169 002	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
	021169 003	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
>ADD>	020387 001	HYDROCHLOROTHIAZIDE;HYZAAR	5608075	MAR 04, 2014			
>ADD>	020387 002	HYDROCHLOROTHIAZIDE;HYZAAR	5608075	MAR 04, 2014			
>ADD>	020402 002	IBUPROFEN POTASSIUM;ADVIL MIGRAINE LIQUI				NP	MAR 16, 2003
>ADD>	021128 001	IBUPROFEN;CHILDREN'S MOTRIN CO	6211246	JUN 10, 2019			
>ADD>	021081 001	INSULIN GLARGINE;LANTUS	5656722	SEP 12, 2014			
	020857 001	LAMIVUDINE;COMBIVIR	6180639	JAN 30, 2018	U-248		
	020564 001	LAMIVUDINE;EPIVIR	6180639	JAN 30, 2018	U-248		
	020596 001	LAMIVUDINE;EPIVIR	6180639	JAN 30, 2018	U-248		
>ADD>	020905 001	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
>ADD>	020905 002	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
>ADD>	020905 003	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
>ADD>	020386 001	LOSARTAN POTASSIUM;COZAAR	5608075	MAR 04, 2014			
>ADD>	020386 002	LOSARTAN POTASSIUM;COZAAR	5608075	MAR 04, 2014			
>ADD>	020357 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
>ADD>	020357 002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
>ADD>	020357 003	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
>ADD>	020357 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
>ADD>	020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021121 001	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372		
	021121 002	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372		
	021121 003	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372	NP	AUG 01, 2003
	019962 001	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 22, 2007		I-194	FEB 05, 2004
			5246714	SEP 21, 2010			
	019962 002	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 22, 2007		I-194	FEB 05, 2004
			5246714	SEP 21, 2010			
	019962 003	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 27, 2007		I-194	FEB 05, 2004
			5246714	SEP 21, 2010			
	019962 004	METOPROLOL SUCCINATE;TOPROL-XL	4957745	SEP 18, 2007	U-107	NS	FEB 05, 2004
			5001161	MAR 19, 2008	U-107	I-194	FEB 05, 2004
			5081154	JAN 14, 2009	U-107		
			4927640	MAY 22, 2007			
			5246714	SEP 21, 2010			
	021208 001	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001
	021208 002	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001
	021208 003	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001
>ADD>	019297 001	MITOXANTRONE HYDROCHLORIDE;NOVANTRONE				I-324	OCT 13, 2003
	020829 002	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228		
	020830 001	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228		
	020830 002	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228		
>ADD>	021204 001	NATEGLINIDE;STARLIX	RE34878	MAR 28, 2006			
>ADD>			5463116	OCT 21, 2012			
>ADD>			5488150	JAN 30, 2013			
>ADD>	021204 002	NATEGLINIDE;STARLIX	RE34878	MAR 28, 2006			
>ADD>			5463116	OCT 21, 2012			
>ADD>			5488150	JAN 30, 2013			
	075269 001	NIFEDIPINE;NIFEDIPINE				PC	JUN 05, 2001
	075269 002	NIFEDIPINE;NIFEDIPINE				PC	JUN 05, 2001
>ADD>	021008 001	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5753618	JUL 08, 2008			
>ADD>	021008 002	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5753618	JUL 08, 2008			
>ADD>	021008 003	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5753618	JUL 08, 2008			
>ADD>	020592 005	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U-149	NCE	SEP 30, 2001
>ADD>			5605897	FEB 25, 2014	U-176		
	021086 001	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
	021086 002	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
	021086 003	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
	021086 004	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
>ADD>	019810 001	OMEPRAZOLE;PRILOSEC	4255431*PED	OCT 05, 2001	U-108	PED	DEC 29, 2001
>ADD>			4636499*PED	JAN 30, 2006			
>ADD>			4853230*PED	OCT 20, 2007	U-108		
>ADD>			5093342*PED	AUG 02, 2010	U-166		
>ADD>			4786505*PED	OCT 20, 2007	U-108		
>ADD>			5599794*PED	AUG 04, 2014	U-166		
>ADD>			6147103*PED	APR 09, 2019			
>ADD>			6166213*PED	APR 09, 2018			
>ADD>			4508905	APR 02, 2002			
>ADD>			6191148*PED	APR 09, 2019			
>ADD>			6150380*PED	MAY 10, 2019			
>ADD>			5629305*PED	AUG 04, 2014	U-188		
			6150380	NOV 10, 2018			
			6147103	OCT 09, 2018			
			6166213	OCT 09, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
			6191148	OCT 09, 2018			
>ADD>	019810 002	OMEPRAZOLE;PRILOSEC	4255431*PED	OCT 05, 2001	U-108	PED	DEC 29, 2001
>ADD>			4636499*PED	JAN 30, 2006			
>ADD>			4853230*PED	OCT 20, 2007	U-108		
>ADD>			5093342*PED	AUG 02, 2010	U-166		
>ADD>			4786505*PED	OCT 20, 2007			
>ADD>			5599794*PED	AUG 04, 2014	U-108		
>ADD>			6147103*PED	APR 09, 2019	U-166		
>ADD>			6166213*PED	APR 09, 2018			
>ADD>			4508905	APR 02, 2002			
>ADD>			6191148*PED	APR 09, 2019			
>ADD>			6150380*PED	MAY 10, 2019			
>ADD>			5629305*PED	AUG 04, 2014			
			6150380	NOV 10, 2018	U-188		
			6147103	OCT 09, 2018			
			6166213	OCT 09, 2018			
			6191148	OCT 09, 2018			
>ADD>	019810 003	OMEPRAZOLE;PRILOSEC	4255431*PED	OCT 05, 2001	U-108	I-229	JUN 29, 2001
>ADD>			4636499*PED	JAN 30, 2006		PED	DEC 29, 2001
>ADD>			4853230*PED	OCT 20, 2007	U-108		
>ADD>			5093342*PED	AUG 02, 2010	U-166		
>ADD>			4786505*PED	OCT 20, 2007	U-108		
>ADD>			5599794*PED	AUG 04, 2014	U-166		
>ADD>			6147103*PED	APR 09, 2019			
>ADD>			6166213*PED	APR 09, 2018			
>ADD>			4508905	APR 02, 2002			
>ADD>			6191148*PED	APR 09, 2019			
>ADD>			6150380*PED	MAY 10, 2019			
>ADD>			5629305*PED	AUG 04, 2014	U-188		
			6150380	NOV 10, 2018			
			6147103	OCT 09, 2018			
			6166213	NOV 10, 2018			
			6191148	OCT 09, 2018			
	021246 001	OSELTAMIVIR PHOSPHATE;TAMIFLU	5763483	DEC 27, 2016	U-376	I-317	NOV 17, 2003
			5866601	FEB 02, 2016		NDF	DEC 14, 2003
			5952375	FEB 02, 2016		NCE	OCT 27, 2004
>ADD>	020897 001	OXYBUTYNIN CHLORIDE;DITROPAN XL	6124355	MAY 22, 2015	U-378		
>ADD>	020897 002	OXYBUTYNIN CHLORIDE;DITROPAN XL	6124355	MAY 22, 2015	U-378		
>ADD>	020897 003	OXYBUTYNIN CHLORIDE;DITROPAN XL	6124355	MAY 22, 2015	U-378		
>ADD>	020262 001	PACLITAXEL;TAXOL	6150398	MAY 08, 2011	U-380		
>ADD>	020988 001	PANTOPRAZOLE SODIUM;PROTONIX	4758579	JUL 19, 2005		NDF	MAR 22, 2004
>ADD>						NCE	FEB 02, 2005
>ADD>	020936 003	PAROXETINE HYDROCHLORIDE;PAXIL CR	4721723	DEC 29, 2006			
>ADD>			4839177	JUN 13, 2006			
>ADD>			5422123	JUN 06, 2012			
>ADD>			5789449	JAN 06, 2009	U-286		
>ADD>			5872132	MAY 19, 2015			
>ADD>			5900423	MAY 19, 2015			
>ADD>			6063927	APR 23, 2019			
>ADD>			6080759	MAY 19, 2015			
>ADD>			6121291	MAR 17, 2017	U-286		
>ADD>			6133289	MAY 19, 2015	U-286		
>ADD>			6172233	JAN 15, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	019627 002	PROPOFOL;DIPRIVAN				I-322	FEB 20, 2004
	020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	4418068	APR 03, 2002			
	020903 001	RIBAVIRIN;REBETOL	6063772	JAN 23, 2016	U-375		
			6172046	SEP 21, 2017	U-377		
	020632 001	SIBUTRAMINE HYDROCHLORIDE;MERIDIA				D-65	FEB 16, 2004
	020632 002	SIBUTRAMINE HYDROCHLORIDE;MERIDIA				D-65	FEB 16, 2004
	020632 003	SIBUTRAMINE HYDROCHLORIDE;MERIDIA				D-65	FEB 16, 2004
>ADD>	020280 001	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018			
>ADD>	020280 002	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018			
>ADD>	020280 003	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018			
>ADD>	020280 005	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018			
>ADD>	020280 008	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018			
>ADD>	020280 009	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018			
>ADD>	021257 001	TRAVOPROST;TRAVATAN	6011062	DEC 22, 2014	U-382	NCE	MAR 16, 2006
>ADD>			5631287	DEC 22, 2014	U-382		
>ADD>			5849792	DEC 22, 2014	U-383		
>ADD>			5889052	AUG 03, 2013	U-383		
>ADD>	021257 002	TRAVOPROST;TRAVATAN	6011062	DEC 22, 2014	U-382	NCE	MAR 16, 2006
>ADD>			5631287	DEC 22, 2014	U-382		
>ADD>			5849792	DEC 22, 2014	U-383		
>ADD>			5889052	AUG 03, 2013	U-383		
	020468 001	TRIAMCINOLONE ACETONIDE;NASACORT AQ	6143329	JUL 03, 2016			
	020759 001	TROVAFLOXACIN MESYLATE;TROVAN	6187341	JAN 20, 2019			
	020759 002	TROVAFLOXACIN MESYLATE;TROVAN	6187341	JAN 20, 2019			
>ADD>	021304 001	VALGANCICLOVIR HYDROCHLORIDE;VALCYT				NE	MAR 29, 2004
	020825 001	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
			5312925	SEP 01, 2012			
	020825 002	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
			5312925	SEP 01, 2012			
	020825 003	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
			5312925	SEP 01, 2012			
	020825 004	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
			5312925	SEP 01, 2012			

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 21ST EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

REFERENCES

NEW DOSING SCHEDULE

D-65 CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS

NEW INDICATION

I-321 JUVENILE RHEUMATOID ARTHRITIS
I-322 USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS
I-323 COLORECTAL CANCER
I-324 REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS

MISCELLANEOUS EXCLUSIVITY CODES

M-6 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUOPHAGE/GLYBURIDE COMBINATION ADDED TO CLIN PHARM AND DOSING AND ADMIN
M-7 CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION

PATENT USE CODE

U-372 METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...
U-373 GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OFGERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-374 KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX
U-375 METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C
U-376 TREATMENT OF INFLUENZA

PATENT AND EXCLUSIVITY TERMS

REFERENCES
PATENT USE CODE

U-377	**METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS**
U-378	**METHOD FOR TREATING INCONTINENCE**
U-379	**METHOD OF TREATING ONYCHROMYCOSIS**
U-380	**COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS**
U-381	**TREATMENT OF HYPERPHOSPHATEMIA**
U-382	**METHOD OF STABLIZING PROSTAGLANDIN**
U-383	**METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION**

*U.S. Government Printing Office: 2001— 472-432/21009

New 21st Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 8367

Charge your order. It's easy!

☐ **Yes,** enter my subscription as follows:

__subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $101.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐–☐

☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

Company or personal name

Additional address/attention line

Street address

City, State, ZIP Code

(____) _____
Daytime phone including area code

Purchase Order No. (optional)

(Credit card expiration date)

(Authorizing Signature)

Thank you for your order!

(10/00)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.